Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Pharma Manufacturing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Pharma Manufacturing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The State of CDMO Funding: 2025 in Review (Part Two)

17:17
 
Share
 

Manage episode 517670351 series 2941835
Content provided by Pharma Manufacturing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Pharma Manufacturing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In part two of our conversation with Brian Scanlan, Advisor of Life Sciences at Edgewater Capital Partners, we explore how today’s CDMO funding trends are shaping the next phase of growth and specialization across the contract research and manufacturing ecosystem.

Brian shares his perspective on:

  • The outlook for cell and gene therapies, where clinical setbacks, overcapacity, and high costs are balanced by steady innovation and cautious optimism;
  • Why “specialization over scale” is defining the next wave of CDMO success, as niche providers in radiopharma, peptides, and other complex modalities gain traction; and
  • How the evolving Biosecure Act and U.S. reshoring efforts are reshaping global supply chains and creating new opportunities for domestic manufacturing.
  continue reading

96 episodes

Artwork
iconShare
 
Manage episode 517670351 series 2941835
Content provided by Pharma Manufacturing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Pharma Manufacturing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In part two of our conversation with Brian Scanlan, Advisor of Life Sciences at Edgewater Capital Partners, we explore how today’s CDMO funding trends are shaping the next phase of growth and specialization across the contract research and manufacturing ecosystem.

Brian shares his perspective on:

  • The outlook for cell and gene therapies, where clinical setbacks, overcapacity, and high costs are balanced by steady innovation and cautious optimism;
  • Why “specialization over scale” is defining the next wave of CDMO success, as niche providers in radiopharma, peptides, and other complex modalities gain traction; and
  • How the evolving Biosecure Act and U.S. reshoring efforts are reshaping global supply chains and creating new opportunities for domestic manufacturing.
  continue reading

96 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play